Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of Maxing Zhixiao Granule in chronic persistent bronchial asthma (heat asthma syndrome)
ChiCTR2000040379Phase 2Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Nov 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Maxing Zhixiao Granule in asthma (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Rate of good asthma control. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
Maxing Zhixiao Granule
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2000040379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040379.